AMENDMENTS TO CLAIMS

Prior to examination please amend the claims as follows:

1. (Original) A method for determining whether a test compound inhibits RNA synthesis of a positive strand RNA virus, comprising:

contacting an isolated replicase complex for the positive strand RNA virus, an isolated viral replicon template RNA for the positive strand RNA virus, a labeled nucleotide analog, and the test compound, under conditions sufficient for *in vitro* RNA synthesis, to form a newly synthesized RNA population comprising the labeled nucleotide analog;

detecting the newly synthesized RNA population comprising the labeled nucleotide analog;

quantitating the newly synthesized RNA population comprising the labeled nucleotide analog to provide a test RNA amount; and

comparing the test RNA amount with a control RNA amount of a control newly synthesized RNA population comprising the labeled nucleotide analog produced in the absence of the test compound, wherein a decrease in the test RNA amount compared to the control RNA amount indicates that the test compound inhibits RNA synthesis of the positive strand RNA virus.

2. (Original) The method of Claim 1, wherein contacting further comprises contacting with 2'-O-methyl-5-methyluridine-5'- triphosphate.

3. (Original) The method of Claim 1, further comprising providing the isolated replicase complex and the isolated viral replicon template RNA by:
transfecting a cell line with a viral replicon RNA or a DNA template for a viral replicon to provide a transfected cell line,
incubating the transfected cell line under conditions suitable for production of viral replicase complexes, and
isolating the replicase complexes and the viral replicon template RNA from the cell membrane fraction of the transfected cells.

4. (Original) The method of Claim 3, wherein the positive strand RNA virus is Hepatitis C Virus and the DNA template for a viral replicon is SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, or SEQ ID NO: 5.

5. (Original) The method of Claim 1, further comprising providing the isolated replicase complex comprising the viral replicon template RNA by incubating a positive strand RNA virus infected primary cell or cell line under conditions suitable for production of viral replicase complexes, and

isolating the replicase complexes comprising the viral replicon template RNA from the cell membrane fraction of the infected cells.

6. (Original) The method of Claim 1, wherein the positive strand RNA virus is Hepatitis C Virus.

7. (Original) The method of Claim 1, wherein the labeled nucleotide analog is an analog capable of being recognized by a specific antibody, an analog which can be recognized via a high specificity binding reaction, or an analog directly detectable as a result of a physical property of the analog.

8 - 13. (Canceled)

14. (Original) The method of Claim 1, wherein the test compound is an RNA synthesis initiation inhibitor.

15. (Original) The method of Claim 1, wherein the test compound is a replicase complex activity inhibitor.

16. (Original) The method of Claim 7, wherein the analog directly detectable as a result of a physical property of the analog is a radioactive nucleotide.

17. (Original) The method of Claim 16, wherein detecting comprises gel electrophoresis.

18. (Original) A method for quantitating newly initiated RNA of a positive strand RNA virus comprising:
contacting an isolated replicase complex for the positive strand RNA virus, an isolated viral replicon template RNA for the positive strand RNA virus, and a labeled nucleotide analog, under conditions sufficient for *in vitro* RNA synthesis, to form a newly synthesized RNA population comprising the labeled nucleotide analog;
hybridizing a probe and the newly synthesized RNA population comprising the labeled nucleotide analog, under stringent hybridization conditions, wherein the probe is complementary to at least a portion of a transcription initiation region of the newly synthesized RNA population;
digesting unhybridized, single-stranded RNA with a single-strand specific ribonuclease to form a protected RNA population comprising the labeled nucleotide analog;
detecting the protected RNA population comprising the labeled nucleotide analog; and
quantitating the protected RNA population comprising the labeled nucleotide analog.

19. (Original) The method of Claim 18, wherein contacting further comprises contacting with 2'-O-methyl-5-methyluridine-5'- triphosphate.

20. (Original) The method of Claim 18, further comprising providing the isolated replicase complex and the isolated viral replicon template RNA by:
transfecting a human hepatosoma cell line with a viral replicon RNA or a DNA template for a viral replicon to provide a transfected cell line,
incubating the transfected cell line under conditions suitable for production of viral replicase complexes, and
isolating the replicase complexes comprising the viral replicon template RNA from the cell membrane fraction of the transfected cells.

21. (Original) The method of Claim 20, wherein the DNA template for the

viral replicon is SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, or SEQ ID NO: 5.

22. (Canceled)

23. (Original) The method of Claim 18, wherein the labeled nucleotide analog is an analog capable of being recognized by a specific antibody, an analog which can be recognized via a high specificity binding reaction, or an analog directly detectable as a result of a physical property of the analog.

24 - 30. (Canceled)

31. (Original) A method for determining whether a test compound is an RNA synthesis initiation inhibitor of a positive strand RNA virus comprising:

contacting an isolated replicase complex for the positive strand RNA virus, an isolated viral replicon template RNA for the positive strand RNA virus, a labeled nucleotide analog, and the test compound, under conditions sufficient for *in vitro* RNA synthesis, to form a newly synthesized RNA population comprising the labeled nucleotide analog;

hybridizing a probe and the newly synthesized RNA population comprising the labeled nucleotide analog, under stringent hybridization conditions, wherein the probe is complementary to at least a portion of an initiation region of the newly synthesized RNA population;

digesting unhybridized, single-stranded RNA with a single-strand specific ribonuclease to form a protected RNA population comprising the labeled nucleotide analog;

detecting the protected RNA population comprising the labeled nucleotide analog;

quantitating the protected RNA population comprising the labeled nucleotide analog to provide a test RNA amount; and

comparing the test RNA amount with a control RNA amount of protected RNA comprising the labeled nucleotide analog but produced in the absence of the test compound, wherein a decrease in the test RNA amount compared to the control RNA amount indicates that the test compound inhibits RNA synthesis initiation of the positive strand RNA virus.

32. (Canceled)

33. (Original) The method of Claim 31, further comprising providing the isolated replicase complex and the isolated viral replicon template RNA by:

transfecting a human hepatosoma cell line with a viral replicon RNA or a DNA template for a viral replicon to provide a transfected cell line,

incubating the transfected cell line under conditions suitable for production of viral replicase complexes, and

isolating the replicase complexes comprising the viral replicon template RNA from the cell membrane fraction of the transfected cells.

34. – 35. (Canceled)

36. The method of Claim 31, wherein the positive strand RNA virus is Hepatitis C Virus.

37. – 50. (Canceled).

51. (New) The method of Claim 18, wherein the positive strand RNA virus is Hepatitis C Virus.